Immunomodulators Market Size, Industry Trends Report | 2031

Segments - Immunomodulators Market by Products (Immunostimulants [Antibodies, Vaccines, and Others] and Immunosuppressants [Antimetabolitics, Antibodies, Glucocoriticoids, Calcineurin Inhibitors, and Others]), Applications (HIV, Respiratory, Oncology, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 - 2031

Author : Raksha Sharma

Fact-checked by : Vineet Pandey

Editor : Vishal Golekar

Report Description

Immunomodulators Market Outlook 2031:

The global immunomodulators market size was valued at USD 217.10 Million in 2022 and is projected to reach USD 389.17 Million by 2031, expanding at a CAGR of 6.7% during the forecast period 2023 - 2031, attributed to the rising prevalence of chronic diseases such as cancer, asthma, multiple sclerosis, and allergic conditions. Moreover, the formation or introduction of genesis of new biologics response modifiers presents a key aspect for the market growth.

Immunomodulators are types of medications and agents that ensure a proper function of the immune system by balancing the immune response. Using these drugs, the resistance of the body is enhanced against various infections. These are widely used to avoid the rejection of organs during transplantation.

The launch of several novel drugs took place to fight against various diseases that include Crohn’s disease, rheumatoid disease, and others. For instance, SQX770, used for the treatment of recurrent herpes labialis, was a tropical immunomodulator that received positive results in phase 2 trials in 2019.

Later, it became the first and only drug to be approved by the US Food and Drug Administration (FDA) to be used for treatment after completing the phase 3 trials with prominent and positive results.

The COVID-19 pandemic had a significant impact on the global immunomodulators market attributed to the increase in the sales of products that are used in the emergency treatment of the COVID patients. Despite the pandemic, a balance has been made between the supply and demand chains by several pharmaceutical companies. These companies are continuously working on enhancing their research & development and improving the management of their supply chain.

Immunomodulators Market Trends, Drivers, Restraints, and Opportunities

For the treatment of Crohn’s disease, the early immunomodulator therapy is widely adopted is a key driver helping the market growth.
Immunotherapeutic agents are being developed and are under clinical trials due to which the immunomodulators market is expected to register considerable growth.
Presence of several unmet clinical needs for the treatment of immune disorders including rheumatoid arthritis especially in developing countries is anticipated to fuel the market growth in the coming years.
Strict & rigid regulations imposed for the approval of immunomodulator antibodies are estimated to act as a restraining point that can hamper the market expansion during the forecast period.
Ongoing research & development programs in order to provide advanced patient care and increasing candidates of pipeline for the treatment of several diseases are the key opportunities for the market.

Scope of the Immunomodulators Market Report

The report on the global immunomodulators market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Immunomodulators Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast
Base Year	2022
Historic Data	2016–2021
Forecast Period	2023–2031
Segmentation	Products (Immunostimulants [Antibodies, Vaccines, and Others] and Immunosuppressants [Antimetabolitics, Antibodies, Glucocoriticoids, Calcineurin Inhibitors, and Others]) and Applications (HIV, Respiratory, Oncology, and Others)
Regional Scope	Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report	Eli Lily and Co.; F.Hoffmann-La Roche Ltd.; Biogen; Bristol-Myers & Squibb Co.; Teva Pharmaceuticals Industries Ltd.; Merck Sharp & Dohme Corp.; Amgen Inc.; and Novartis AG

Immunomodulators Market Segment Insights

Immunosuppressant is expected to dominate the market

On the basis of products, the global immunomodulators market is bifurcated into immunostimulants and immunosuppressants. The immunostimulants segment is further divided into antibodies, vaccines, and others while the immunosuppressant segment is divided into antimetabolitics, antibodies, glucocoriticoids, calcineurin inhibitors, and others.

The immunosuppressant segment held a major share of the market in 2019 and is expected to dominate the market in the coming years owing to the availability of a wide range of therapeutics including monoclonal antibodies, cyclosporine, azathioprine, and corticosteroids. Moreover, a wide range of immunosuppressant drugs are available for the treatment of several autoimmune diseases including alopecia areata, psoriasis, lupus, and others.

Others segment is anticipated to grow at a significant rate

Based on applications, the market is segmented into HIV, respiratory, oncology, and others. The others segment is anticipated to grow at a significant rate during the projected period owing to various initiatives taken to develop drugs that can fulfill the unmet needs of several infectious diseases.

Furthermore, the segment growth is attributed to the expected launch of immunomodulatory therapies that can be used for the treatment of multiple sclerosis.

North America is estimated to dominate the market

In terms of regions, the global immunomodulators market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a large revenue share of the market in 2019 and is estimated to dominate the market during the forecast period owing to the high number of the targeted population having diseases.

Moreover, the rising demand for advanced therapy for the treatment of multiple sclerosis using these immunotherapeutic agents and immunomodulator-based treatment by several end-users in the region present another major factor driving the regional market growth. Various governments’ supportive initiatives to ensure a high level of public awareness about the disease and availability of its therapy in the region are expected to help boost the regional market growth.

Segments

The global immunomodulators market has been segmented on the basis of

Products

Immunostimulants
- Antibodies
- Vaccines
- Others
Immunosuppressants
- Antimetabolitics
- Antibodies
- Glucocoriticoids
- Calcineurin Inhibitors
- Others

Applications

HIV
Respiratory
Oncology
Others

Regions

Asia Pacific
North America
Latin America
Europe
Middle East & Africa

Key Players

Eli Lily and Co.
F.Hoffmann-La Roche Ltd.
Biogen
Bristol-Myers & Squibb Co.
Teva Pharmaceuticals Industries Ltd.
Merck Sharp & Dohme Corp.
Amgen Inc.
Novartis AG

Competitive Landscape

Key players competing in the global immunomodulators market are Eli Lily and Co.; F.Hoffmann-La Roche Ltd.; Biogen; Bristol-Myers & Squibb Co.; Teva Pharmaceuticals Industries Ltd.; Merck Sharp & Dohme Corp.; Amgen Inc.; and Novartis AG.

Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally. Moreover, branded therapies are anticipated to expire, which is expected to provide a profitable growth to the market.

Immunomodulators Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Immunomodulators Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Immunomodulators Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Immunomodulators Market - Supply Chain
  4.5. Global Immunomodulators Market Forecast
     4.5.1. Immunomodulators Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Immunomodulators Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. Immunomodulators Market Absolute $ Opportunity
5. Global Immunomodulators Market Analysis and Forecast by Applications
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Applications
     5.2.2. Y-o-Y Growth Projections by Applications
  5.3. Immunomodulators Market Size and Volume Forecast by Applications
     5.3.1. HIV Respiratory Oncology Others
  5.4. Absolute $ Opportunity Assessment by Applications
  5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Immunomodulators Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Immunomodulators Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Immunomodulators Demand Share Forecast, 2019-2026
7. North America Immunomodulators Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Immunomodulators Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Immunomodulators Market Size and Volume Forecast by Applications
     7.4.1. HIV Respiratory Oncology Others
  7.5. Basis Point Share (BPS) Analysis by Applications
  7.6. Y-o-Y Growth Projections by Applications
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Immunomodulators Demand Share Forecast, 2019-2026
8. Latin America Immunomodulators Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Immunomodulators Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Immunomodulators Market Size and Volume Forecast by Applications
     8.4.1. HIV Respiratory Oncology Others
  8.5. Basis Point Share (BPS) Analysis by Applications
  8.6. Y-o-Y Growth Projections by Applications
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Immunomodulators Demand Share Forecast, 2019-2026
9. Europe Immunomodulators Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Immunomodulators Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Immunomodulators Market Size and Volume Forecast by Applications
     9.4.1. HIV Respiratory Oncology Others
  9.5. Basis Point Share (BPS) Analysis by Applications
  9.6. Y-o-Y Growth Projections by Applications
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Immunomodulators Demand Share Forecast, 2019-2026
10. Asia Pacific Immunomodulators Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Immunomodulators Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Immunomodulators Market Size and Volume Forecast by Applications
     10.4.1. HIV Respiratory Oncology Others
  10.5. Basis Point Share (BPS) Analysis by Applications
  10.6. Y-o-Y Growth Projections by Applications
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Immunomodulators Demand Share Forecast, 2019-2026
11. Middle East & Africa Immunomodulators Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Immunomodulators Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Immunomodulators Market Size and Volume Forecast by Applications
     11.4.1. HIV Respiratory Oncology Others
  11.5. Basis Point Share (BPS) Analysis by Applications
  11.6. Y-o-Y Growth Projections by Applications
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Immunomodulators Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Immunomodulators Market: Market Share Analysis
  12.2. Immunomodulators Distributors and Customers
  12.3. Immunomodulators Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Eli Lily and Co. F.Hoffmann-La Roche Ltd. Biogen Bristol-Myers & Squibb Co. Teva Pharmaceuticals Industries Ltd. Merck Sharp & Dohme Corp.